サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435118

心房中隔欠損症市場：症状別、用途別-2024-2030年の世界予測

Atrial Septal Defect Market by Symptoms (Dyspnea, Fatigue, Frequent Respiratory Infections), Application (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 189 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
心房中隔欠損症市場：症状別、用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心房中隔欠損症市場規模は2023年に57億米ドルと推計され、2024年には60億5,000万米ドルに達し、CAGR 6.29%で2030年には87億3,000万米ドルに達すると予測されます。

心房中隔欠損症の世界市場

主な市場の統計
基準年[2023］ 57億米ドル
予測年[2024］ 60億5,000万米ドル
予測年 [2030] 87億3,000万米ドル
CAGR（%） 6.29%
心房中隔欠損症 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは心房中隔欠損症市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、心房中隔欠損症市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-心房中隔欠損症市場の市場規模および予測は？

2-心房中隔欠損症市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-心房中隔欠損症市場における技術動向と規制の枠組みは？

4-心房中隔欠損症市場における主要ベンダーの市場シェアは？

5-心房中隔欠損症市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 遺伝性心疾患の有病率の上昇
      • 政府および公的機関による心房中隔欠損症に関する啓発キャンペーンの拡大
      • 心臓MRI検査の導入
    • 抑制要因
      • 経皮的ASD閉鎖に対する解剖学的限界
    • 機会
      • 先天性心疾患の治療における技術の進歩
      • ASD治療に対する政府の有利な償還
    • 課題
      • ASD手術中の合併症と副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 心房中隔欠損症市場症状別

  • 呼吸困難
  • 倦怠感
  • 頻繁な呼吸器感染症
  • 動悸
  • 脚と足のむくみ

第7章 心房中隔欠損症市場：用途別

  • 外来手術センター
  • 病院
  • 専門クリニック

第8章 南北アメリカの心房中隔欠損症市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の心房中隔欠損症市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの心房中隔欠損症市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Asklepion Pharmaceuticals, LLC
    • AtriCure, Inc
    • Carag AG
    • GE HealthCare Technologies, Inc.
    • Johnson & Johnson Services, Inc.
    • Lepu Medical Technology（Beijing）Co., Ltd
    • Lifetech Scientific
    • Medtronic PLC
    • Occlutech GmbH
    • Siemens AG
    • W. L. Gore & Associates, Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ATRIAL SEPTAL DEFECT MARKET RESEARCH PROCESS
  • FIGURE 2. ATRIAL SEPTAL DEFECT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ATRIAL SEPTAL DEFECT MARKET DYNAMICS
  • FIGURE 7. ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2023 VS 2030 (%)
  • FIGURE 8. ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ATRIAL SEPTAL DEFECT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ATRIAL SEPTAL DEFECT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ATRIAL SEPTAL DEFECT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 6. ATRIAL SEPTAL DEFECT MARKET SIZE, BY DYSPNEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ATRIAL SEPTAL DEFECT MARKET SIZE, BY FATIGUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ATRIAL SEPTAL DEFECT MARKET SIZE, BY FREQUENT RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ATRIAL SEPTAL DEFECT MARKET SIZE, BY HEART PALPITATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ATRIAL SEPTAL DEFECT MARKET SIZE, BY SWELLING OF LEGS & FEET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. ATRIAL SEPTAL DEFECT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ATRIAL SEPTAL DEFECT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ATRIAL SEPTAL DEFECT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYMPTOMS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ATRIAL SEPTAL DEFECT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ATRIAL SEPTAL DEFECT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 102. ATRIAL SEPTAL DEFECT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ATRIAL SEPTAL DEFECT MARKET LICENSE & PRICING
目次
Product Code: MRR-CA17E905E9D5

[189 Pages Report] The Atrial Septal Defect Market size was estimated at USD 5.70 billion in 2023 and expected to reach USD 6.05 billion in 2024, at a CAGR 6.29% to reach USD 8.73 billion by 2030.

Global Atrial Septal Defect Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.70 billion
Estimated Year [2024] USD 6.05 billion
Forecast Year [2030] USD 8.73 billion
CAGR (%) 6.29%
Atrial Septal Defect Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Atrial Septal Defect Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atrial Septal Defect Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Atrial Septal Defect Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Asklepion Pharmaceuticals, LLC, AtriCure, Inc, Carag AG, GE HealthCare Technologies, Inc., Johnson & Johnson Services, Inc., Lepu Medical Technology (Beijing) Co., Ltd, Lifetech Scientific, Medtronic PLC, Occlutech GmbH, Siemens AG, and W. L. Gore & Associates, Inc..

Market Segmentation & Coverage

This research report categorizes the Atrial Septal Defect Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Symptoms
    • Dyspnea
    • Fatigue
    • Frequent Respiratory Infections
    • Heart Palpitations
    • Swelling of Legs & Feet
  • Application
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Atrial Septal Defect Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atrial Septal Defect Market?

3. What are the technology trends and regulatory frameworks in the Atrial Septal Defect Market?

4. What is the market share of the leading vendors in the Atrial Septal Defect Market?

5. Which modes and strategic moves are suitable for entering the Atrial Septal Defect Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Atrial Septal Defect Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalences of genetic heart disorders
      • 5.1.1.2. Growing awareness campaigns regarding atrial septal defects by government and public organizations
      • 5.1.1.3. Adoption of cardiac MRI procedures
    • 5.1.2. Restraints
      • 5.1.2.1. Anatomical limitations to percutaneous ASD closure
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the treatment of congenital heart diseases
      • 5.1.3.2. Favorable government reimbursements for ASD treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Complication and side effects during ASD surgeries
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Atrial Septal Defect Market, by Symptoms

  • 6.1. Introduction
  • 6.2. Dyspnea
  • 6.3. Fatigue
  • 6.4. Frequent Respiratory Infections
  • 6.5. Heart Palpitations
  • 6.6. Swelling of Legs & Feet

7. Atrial Septal Defect Market, by Application

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Americas Atrial Septal Defect Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Atrial Septal Defect Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Atrial Septal Defect Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Asklepion Pharmaceuticals, LLC
    • 12.1.3. AtriCure, Inc
    • 12.1.4. Carag AG
    • 12.1.5. GE HealthCare Technologies, Inc.
    • 12.1.6. Johnson & Johnson Services, Inc.
    • 12.1.7. Lepu Medical Technology (Beijing) Co., Ltd
    • 12.1.8. Lifetech Scientific
    • 12.1.9. Medtronic PLC
    • 12.1.10. Occlutech GmbH
    • 12.1.11. Siemens AG
    • 12.1.12. W. L. Gore & Associates, Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing